TAOS1，一种用于晚期食管鳞状细胞癌的新型标志物。
TAOS1, a novel marker for advanced esophageal squamous cell carcinoma.
作者信息
Komatsu Yoshinao, Hibi Kenji, Kodera Yasuhiro, Akiyama Seiji, Ito Katsuki, Nakao Akimasa
机构信息
Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan.
出版信息
Anticancer Res. 2006 May-Jun;26(3A):2029-32.
BACKGROUND
TAOS1 (tumor amplified and overexpressed sequence 1) was recently cloned and found to be possibly important in driving the amplification of 11q13 in oral squamous cell carcinoma (SCC).
MATERIALS AND METHODS
Quantitative RT-PCR was performed to determine the possible relationship between TAOS1 gene expression levels and clinicopathological features in esophageal SCC.
RESULTS
TAOS1 overexpression was observed in 7 out of 38 (18%) esophageal SCCs and CCND1 overexpression was observed in 4 out of 38 (11%), suggesting that TAOS1 was more frequently overexpressed than CCND1 in esophageal SCC. The examination of the correlation of TAOS1 overexpression with the clinicopathological features revealed a significant difference in lymph node metastasis (p = 0.014) and a trend towards advanced TNM stages (p = 0.074).
CONCLUSION
The present results suggest that TAOS1 might serve as a new marker for predicting the malignancy of esophageal SCC.
背景
TAOS1（肿瘤扩增及过表达序列1）最近被克隆出来，并且发现在口腔鳞状细胞癌（SCC）中对11q13的扩增可能起重要作用。
材料与方法
采用定量逆转录聚合酶链反应（qRT-PCR）来确定TAOS1基因表达水平与食管SCC临床病理特征之间的可能关系。
结果
在38例食管SCC中有7例（18%）观察到TAOS1过表达，38例中有4例（11%）观察到CCND1过表达，这表明在食管SCC中TAOS1比CCND1更频繁地过表达。对TAOS1过表达与临床病理特征的相关性检查显示，在淋巴结转移方面有显著差异（p = 0.014），并且在TNM晚期阶段有一定趋势（p = 0.074）。
结论
目前的结果表明，TAOS1可能作为预测食管SCC恶性程度的一个新标志物。
Zotero 插件